Edoxaban Tosylate
FDA-approved product (tablet, oral), marketed as Savaysa.
- Registered studies
- 22
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atrial fibrillation
- Deep vein thrombosis
- Pulmonary embolism
- Recurrent thrombophlebitis
- Stroke
- Venous thromboembolism
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Direct factor xa inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
22registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Edoxaban Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01203098 · start 2008-07
Registered record
- Registry ID
- NCT01203098
- Conditions
- Venous Thromboembolism; Thromboembolism; Thrombosis; Embolism and Thrombosis; Deep Vein Thrombosis; Arthroplasty, Replacement, Hip
- Interventions
- DU-176b 15mg; DU-176b 30mg; Enoxaparin sodium 20 mg (=2000IU)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2009-06
- Enrolment
- 264
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVenous Thromboembolism; Thromboembolism; Thrombosis; Embolism and Thrombosis +2 moreInterventionDU-176b 15mg; DU-176b 30mg; Enoxaparin sodium 20 mg (=2000IU)PhasePhase 2Registry statusCompletedDU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
NCT00806624 · start 2007-10
Registered record
- Registry ID
- NCT00806624
- Conditions
- Atrial Fibrillation; Stroke
- Interventions
- DU-176b tablets; DU-176b tablets; Warfarin tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2009-11
- Enrolment
- 234
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation; StrokeInterventionDU-176b tablets; DU-176b tablets; Warfarin tabletsPhasePhase 2Registry statusCompletedA Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
NCT00504556 · start 2007-06
Registered record
- Registry ID
- NCT00504556
- Conditions
- Atrial Fibrillation; Thromboembolism
- Interventions
- Edoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b); warfarin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-06
- Completion
- 2008-06
- Enrolment
- 1,146
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation; ThromboembolismInterventionEdoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b) +1 morePhasePhase 2Registry statusCompletedLate Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation
NCT00829933 · start 2007-03
Registered record
- Registry ID
- NCT00829933
- Conditions
- Atrial Fibrillation
- Interventions
- DU-176b tablets; Warfarin potassium tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2008-09
- Enrolment
- 536
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionDU-176b tablets; Warfarin potassium tabletsPhasePhase 2Registry statusCompletedA Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
NCT01203072 · start 2006-07
Registered record
- Registry ID
- NCT01203072
- Conditions
- Venous Thromboembolism; Deep Vein Thrombosis; Total Knee Arthroplasty
- Interventions
- DU-176b; DU-176b; DU-176b; DU-176b; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-07
- Completion
- 2008-07
- Enrolment
- 523
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVenous Thromboembolism; Deep Vein Thrombosis; Total Knee ArthroplastyInterventionDU-176b; DU-176b; DU-176b; DU-176b +1 morePhasePhase 2Registry statusCompletedA Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
NCT00398216 · start 2006-05
Registered record
- Registry ID
- NCT00398216
- Conditions
- Thrombosis; Hip Replacement
- Interventions
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2007-06
- Enrolment
- 903
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThrombosis; Hip ReplacementInterventionDU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitorPhasePhase 2Registry statusCompletedStudy of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
NCT00107900 · start 2005-01
Registered record
- Registry ID
- NCT00107900
- Conditions
- Arthroplasty, Replacement, Hip; Thrombosis
- Interventions
- DU-176b
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2005-12
- Enrolment
- 606
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArthroplasty, Replacement, Hip; ThrombosisInterventionDU-176bPhasePhase 2Registry statusCompleted